We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Celgene Oral Psoriasis Drug Hits Primary Endpoint in Phase III
Celgene Oral Psoriasis Drug Hits Primary Endpoint in Phase III
March 4, 2013
Celgene’s oral psoriasis drug apremilast proved more effective than placebo in a late-stage study, preparing the company for an NDA filing in the second half of this year.